SCHEMBL4440461

SCHEMBL4440461

CC(=O)OCC(=O)C1(c2ccccc2Cl)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.47
GRIN1 Q05586 4/20 0.37
GRIN2A Q12879 4/20 0.37
HPGD P15428 2/20 0.37
GRIN2D O15399 2/20 0.37
GRIN3B O60391 2/20 0.37
GRIN2B Q13224 2/20 0.37
GRIN2C Q14957 2/20 0.37
GRIN3A Q8TCU5 2/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
SLC6A4 P31645 2/20 0.35
OPRK1 P41145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4441712 0.79 HDAC4 (0.50) HDAC4HPGDALDH1A1SMN1; SMN2RAB9A
SCHEMBL4440439 0.78 OPRM1 (0.47) HPGDALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL4445381 0.78 HDAC4 (0.54) HDAC4GRIN1GRIN2AGRIN2DGRIN3B
SCHEMBL4436214 0.76 SMN1; SMN2 (0.47) HDAC4HPGDUSP2ALDH1A1SMN1; SMN2
SCHEMBL4447380 0.73 MAPT (0.51) HDAC4ALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL4284674 0.72 HDAC4 (0.59) HDAC4GRIN1GRIN2AALDH1A1CRHBP
SCHEMBL30790659 0.72 HDAC4 (0.59) HDAC4GRIN1GRIN2AALDH1A1CRHBP
SCHEMBL8747357 0.72 HDAC4 (0.59) HDAC4GRIN1GRIN2AGRIN2DGRIN3B
SCHEMBL29077524 0.71 HDAC4 (0.57) HDAC4GRIN1GRIN2AGRIN2DGRIN3B
SCHEMBL4439542 0.70 ALDH1A1 (0.36) HPGDALDH1A1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101646652-A Quinoline derivatives and pharmaceutical compositions comprising them for selectin inhibition WYETH CORP US 2010-02-10 CN disclosed
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE HDAC4 2710/4885GRIN1 554/4885GRIN2A 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.